Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the administration of a potentially immunogenic substance. Another method contemplates tolerizing a subject to a therapeutic molecule that is or is capable of being immunogenic by the administration of CTLA-4. Various embodiments of CTLA-4 are also disclosed.

 
Web www.patentalert.com

< Human monoclonal antibody against TGF-.beta. type II receptor and medicinal use thereof

> Vanilloid receptor ligands and their use in treatments

> Substituted heterocyclic compounds and methods of use

~ 00540